.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Long-term extension data are important when treating a chronic progressive disorder because early trial gains may be difficult to sustain. Follow-up from EXPAND and its extension showed that patients who received continuous siponimod maintained lower risks of six-month confirmed disability progression and cognitive processing-speed worsening compared with participants who initially received placebo and later switched to siponimod. MRI measures also supported continued suppression of disease activity and brain atrophy. These findings strengthen the case for early initiation of effective therapy in patients with active secondary progressive MS, although the extension is open-label and therefore less robust than the randomized core study. For HCPs, the key clinical lesson is that delaying treatment in an actively inflammatory SPMS phenotype may leave avoidable disability on the table. At the same time, treatment requires ongoing assessment of efficacy, adverse effects and disease activity. The study fits IANCON's emphasis on long-term management of complex neurological disease and demonstrates how extension studies can complement randomized trial evidence.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Long-term extension data are important when treating a chronic progressive disorder because early trial gains may be difficult to sustain. Follow-up from EXPAND and its extension showed that patients who received continuous siponimod maintained lower risks of six-month confirmed disability progression and cognitive processing-speed worsening compared with participants who initially received placebo and later switched to siponimod. MRI measures also supported continued suppression of disease activity and brain atrophy. These findings strengthen the case for early initiation of effective therapy in patients with active secondary progressive MS, although the extension is open-label and therefore less robust than the randomized core study. For HCPs, the key clinical lesson is that delaying treatment in an actively inflammatory SPMS phenotype may leave avoidable disability on the table. At the same time, treatment requires ongoing assessment of efficacy, adverse effects and disease activity. The study fits IANCON's emphasis on long-term management of complex neurological disease and demonstrates how extension studies can complement randomized trial evidence.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
